AR and triple-negative breast carcinoma: Beyond the licensed indication of abiraterone in prostate cancer, studies of abiraterone in breast cancer have been reported and the response rates have been modest.26, –28 The results of these studies suggest that AR is not likely to be the main driver in endocrine-resistant or triple-negative breast cancer.